<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450203</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000536013</org_study_id>
    <secondary_id>MRC-ST03</secondary_id>
    <secondary_id>EU-20710</secondary_id>
    <secondary_id>ISRCTN46020948</secondary_id>
    <secondary_id>2006-000811-12</secondary_id>
    <secondary_id>00316/0221/001</secondary_id>
    <nct_id>NCT00450203</nct_id>
  </id_info>
  <brief_title>Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer</brief_title>
  <acronym>ST03</acronym>
  <official_title>A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres) MRI and PET/CT Sub-studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professor David Cunningham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical Research Council</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as epirubicin, cisplatin, and capecitabine, work
      in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing. Monoclonal antibodies, such as bevacizumab, and small molecule
      tyrosine kinase inhibitors, such as lapatinib, can block tumor growth in different ways. Some
      block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
      them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor
      cells by blocking blood flow to the tumor. Lapatinib targets a specific growth receptor,
      HER-2. Chemotherapy together with bevacizumab or lapatinib, in HER-2 positive tumours, may
      kill more tumor cells.

      PURPOSE: This randomized phase II/III trial is studying the side effects and how well giving
      combination chemotherapy together with bevacizumab works compared with combination
      chemotherapy alone in treating patients with previously untreated stomach cancer,
      gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery.
      The feasibility study is studying the safety of adding lapatinib to chemotherapy in patients
      with HER-2 positive previously untreated stomach cancer, gastroesophageal junction cancer or
      lower oesophageal cancer that can be removed by surgery. The feasibility study will also
      assess the feasibility of timely HER-2 testing and estimate the HER-2 positivity rate in this
      patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Assess the safety and efficacy of neoadjuvant and adjuvant chemotherapy comprising
           epirubicin hydrochloride, cisplatin, and capecitabine with or without bevacizumab in
           patients with previously untreated, resectable gastric, gastroesophageal junction or
           lower oesophageal cancer.

        -  Assess the safety of neoadjuvant and adjuvant chemotherapy comprising epirubicin
           hydrochloride, cisplatin, and capecitabine with or without lapatinib in patients with
           HER-2 positive previously untreated, resectable gastric, gastroesophageal junction or
           lower oesophageal cancer.

      OUTLINE: This is a multicenter, randomized, open-label, controlled study. Patients are
      randomized to 1 of 4 treatment arms.

        -  Arm I and II: Patients receive epirubicin hydrochloride IV and cisplatin IV over 4 hours
           on day 1 and capecitabine orally twice daily on days 1-21. Treatment repeats every 21
           days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

      Patients undergo surgery 5-6 weeks after completion of chemotherapy. Patients then receive 3
      additional courses of chemotherapy beginning 6-10 weeks after surgery.

        -  Arm II: Patients receive bevacizumab IV over 30-90 minutes, epirubicin hydrochloride IV,
           and cisplatin IV over 4 hours on day 1 and capecitabine orally twice daily on days 1-21.
           Treatment repeats every 21 days for up to 3 courses in the absence of disease
           progression or unacceptable toxicity.

      Patients undergo surgery 5-8 weeks after completion of chemotherapy. Patients then receive 3
      additional courses of chemotherapy and bevacizumab beginning 6-10 weeks after surgery.
      Patients then receive maintenance therapy comprising bevacizumab IV over 30-90 minutes on day
      1. Maintenance therapy repeats every 21 days for up to 6 courses in the absence of disease
      progression or unacceptable toxicity.

        -  Arm IV: Patients receive lapatinib orally once daily, epirubicin hydrochloride IV, and
           cisplatin IV over 4 hours on day 1 and capecitabine orally twice daily on days 1-21.
           Treatment repeats every 21 days for up to 3 courses in the absence of disease
           progression or unacceptable toxicity.

      Patients undergo surgery 5-8 weeks after completion of chemotherapy. Patients then receive 3
      additional courses of chemotherapy and lapatinib beginning 6-10 weeks after surgery. Patients
      then receive maintenance therapy comprising lapatinib orally once daily on days 1-21.
      Maintenance therapy repeats every 21 days for up to 6 courses in the absence of disease
      progression or unacceptable toxicity.

      Quality of life is assessed at baseline, during treatment, and during the follow-up period.

      After completion of study treatment, patients are followed at 9, 18, and 27 weeks after the
      start of course 4, 1 year post surgery, every 6 months for 2 years, and then annually
      thereafter.

      PROJECTED ACCRUAL: A total of 1063 patients were recruited to the bevacizumab comparison of
      the study (now closed to recruitment) and 40 patients with HER-2 positive tumours will be
      recruited into the ST03 feasibility study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>at the end of phase II and phase III</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>end of trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>end of trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related morbidity</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates to pre-operative treatment</measure>
    <time_frame>at phase II review and at end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical resection rates</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HER-2 Positivity Rate</measure>
    <time_frame>End of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of centralised HER-2 testing</measure>
    <time_frame>After 60 patients tested and then after 110 patients tested and then at end of trial</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1103</enrollment>
  <condition>Oesophagogastric Cancer</condition>
  <arm_group>
    <arm_group_label>ECX + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ECX + Bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epirubicin, Cisplatin and Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ECX chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECX + Lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ECX + Lapatinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.</description>
    <arm_group_label>ECX + Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)</description>
    <arm_group_label>ECX + Bevacizumab</arm_group_label>
    <arm_group_label>Epirubicin, Cisplatin and Capecitabine</arm_group_label>
    <arm_group_label>ECX + Lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)</description>
    <arm_group_label>ECX + Bevacizumab</arm_group_label>
    <arm_group_label>Epirubicin, Cisplatin and Capecitabine</arm_group_label>
    <arm_group_label>ECX + Lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)</description>
    <arm_group_label>ECX + Bevacizumab</arm_group_label>
    <arm_group_label>Epirubicin, Cisplatin and Capecitabine</arm_group_label>
    <arm_group_label>ECX + Lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>3 cycles of ECX chemotherapy post operatively</description>
    <arm_group_label>ECX + Bevacizumab</arm_group_label>
    <arm_group_label>Epirubicin, Cisplatin and Capecitabine</arm_group_label>
    <arm_group_label>ECX + Lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.</description>
    <arm_group_label>ECX + Bevacizumab</arm_group_label>
    <arm_group_label>Epirubicin, Cisplatin and Capecitabine</arm_group_label>
    <arm_group_label>ECX + Lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <description>3 cycles of pre-operative ECX chemotherapy.</description>
    <arm_group_label>ECX + Bevacizumab</arm_group_label>
    <arm_group_label>Epirubicin, Cisplatin and Capecitabine</arm_group_label>
    <arm_group_label>ECX + Lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.</description>
    <arm_group_label>ECX + Lapatinib</arm_group_label>
    <other_name>Tyverb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        This is a combined eligibility criteria for both bevacizumab comparison and the lapatinib
        feasibility study. Please note the bevacizumab comparison closed to recruitment on 28th
        March 2014.

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed gastric or type I, II or III gastroesophageal junction
             adenocarcinoma or lower oesophageal

        Gastric and Type III junctional tumours should be Stage Ib (T1 N1, T2a/b N0), II, III or
        stage IV (T4 N1 or N2) with no evidence of distant metastases (M0)

        Lower oesophageal and Type I and II junctional tumours should be Stage II to Stage IVa (T1
        N1, T2 N1, T3 N0-1, but not T2N0). T4 (N0 or N1) tumours are also eligible providing that
        they involve only the crura OR invade only the mediastinal pleura. Patients with nodal
        disease affecting the origin of the left gastric and splenic artery or coeliac axis (staged
        as M1a) are also eligible.

          -  Resectable disease

          -  Previously untreated disease

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0 or 1

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL (can be post transfusion)

          -  WBC ≥ 3,000/mm^3

          -  Glomerular filtration rate ≥ 60 mL/min

          -  Proteinuria ≤ 1 g by 24-hour urine collection

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  ALT and AST ≤ 2.5 times ULN

          -  Alkaline phosphatase ≤ 3 times ULN (in the absence of liver metastases)

          -  INR ≤ 1.5

          -  PTT ≤ 1.5 times ULN

          -  FEV_1 ≥ 1.5 L

          -  Cardiac ejection fraction ≥ 50% by MUGA scan or echocardiogram

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Must be fit enough to receive protocol treatment

          -  No other malignancies within the past 5 years except for curatively treated basal cell
             carcinoma of the skin and/or in situ carcinoma of the cervix

          -  No prior or concurrent significant medical conditions, including any of the following:

               -  Cerebrovascular disease (including transient ischemic attack and stroke) within
                  the past year

               -  Cardiovascular disease, including the following:

                    -  Myocardial infarction within the past year

                    -  Uncontrolled hypertension while receiving chronic medication

                    -  Unstable angina

                    -  New York Heart Association class II-IV congestive heart failure

                    -  Serious cardiac arrhythmia requiring medication

               -  Major trauma within the past 28 days

               -  Serious nonhealing wound, ulcer, or bone fracture

               -  Evidence of bleeding diathesis or coagulopathy

               -  Recent history of any active gastrointestinal inflammatory condition (e.g.,
                  peptic ulcer disease, diverticulitis, or inflammatory bowel disease)

                    -  If patients have a known diagnosis of any of the above, evidence of disease
                       control is required by negative endoscopy within the past 28 days

          -  No severe tinnitus

          -  No lack of physical integrity of the upper gastrointestinal tract, malabsorption
             syndrome, or inability to take oral medication

          -  No known peripheral neuropathy ≥ 1 (absence of deep tendon reflexes as the sole
             neurological abnormality does not render the patient ineligible)

          -  No known dihydropyrimidine dehydrogenase deficiency

          -  No history of interstitial lung disease or radiological evidence of lung fibrosis

          -  No known allergy to any of the following:

               -  Chinese hamster ovary cell proteins

               -  Other recombinant human or humanized antibodies

               -  Any excipients of bevacizumab formulation or platinum compounds

               -  Any other components of the study drugs

        Due to an increase in perforations associated with self-expandable metal stents in patients
        with colorectal cancer receiving bevacizumab, patients with an oesophageal or gastric stent
        (metal or biodegradable) in situ are ineligible for the study.

        PRIOR CONCURRENT THERAPY:

          -  No prior anthracycline

          -  More than 28 days since prior major surgery or open biopsy

          -  More than 10 days since prior thrombolytic therapy

          -  No concurrent thrombolytic therapy

          -  No concurrent dipyridamole

          -  No concurrent capecitabine or sorivudine (or sorivudine analogues [e.g., brivudine])

          -  No chronic, daily high-dose acetylsalicylic acid (&gt; 325 mg/day) or nonsteroidal
             anti-inflammatory drugs

          -  No chronic corticosteroids (≥ 10 mg/day methylprednisolone equivalent)

               -  Inhaled steroids allowed

          -  No other concurrent cytotoxic agents

          -  No other concurrent investigational drugs

          -  No concurrent radiotherapy

          -  Low molecular weight heparin allowed

          -  More than 7 days since prior CYP3A4 inhibitor therapy

          -  More than 14 days since prior CYP3A4 inducer therapy

          -  More than 6 months since prior amiodarone therapy

          -  More than 14 days since prior St John's Wort, modafinil, ginkgo biloba, kava, grape
             seed, valerian, ginseng, echinacea and evening primrose oil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cunningham, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Kleovoulou</last_name>
    <phone>0207 670 4801</phone>
    <email>n.kleovoulou@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>England</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Geldart</last_name>
      <phone>44-1202-726-088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <state>England</state>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen J. Falk, MD</last_name>
      <phone>44-117-928-3074</phone>
      <email>stephen.falk@ubht.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cumberland Infirmary</name>
      <address>
        <city>Carlisle</city>
        <state>England</state>
        <zip>CA2 7HY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Doncaster Royal Infirmary</name>
      <address>
        <city>Doncaster</city>
        <state>England</state>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Wadsley</last_name>
      <phone>44-1302-366-666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Centre at Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>England</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary W. Middleton</last_name>
      <phone>44-1483-570-122</phone>
      <email>gmiddleton@royalsurrey.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huddersfield Royal Infirmary</name>
      <address>
        <city>Huddersfield, West Yorks</city>
        <state>England</state>
        <zip>HD3 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Dent</last_name>
      <phone>44-1484-342-000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew T. Seymour, MA, MD, FRCP</last_name>
      <phone>44-113-206-6400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lincoln County Hospital</name>
      <address>
        <city>Lincoln</city>
        <state>England</state>
        <zip>LN2 5QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Smith, MD</last_name>
      <phone>44-151-525-5980</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Slater, MD</last_name>
      <phone>44-20-7601-8391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Kent Oncology Centre at Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>England</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Waters, MD</last_name>
      <phone>44-1622-729-000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Was Mansoor, MD</last_name>
      <phone>44-845-226-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Smith, MD</last_name>
      <phone>44-151-334-1155</phone>
      <email>david.smith@ccotrust.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Treatment at Newcastle General Hospital</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fareeda Coxon, MD</last_name>
      <phone>44-191-256-3551</phone>
      <email>fareeda.coxon@nuth.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>England</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dorset Cancer Centre</name>
      <address>
        <city>Poole Dorset</city>
        <state>England</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Berkshire Cancer Centre at Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <state>England</state>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joss Adams, MD</last_name>
      <phone>44-118-322-7878</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rochdale Infirmary</name>
      <address>
        <city>Rochdale</city>
        <state>England</state>
        <zip>0L12 0NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Salisbury District Hospital</name>
      <address>
        <city>Salisbury</city>
        <state>England</state>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim J. Iveson, MD</last_name>
      <phone>44-1722-336-262 ext. 4688</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wexham Park Hospital</name>
      <address>
        <city>Slough, Berkshire</city>
        <state>England</state>
        <zip>SL2 4HL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcia Hall, MD</last_name>
      <phone>44-1753-634-364</phone>
      <email>marcia.hall@nhs.net.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim J. Iveson, MD</last_name>
      <phone>44-23-8079-6802</phone>
      <email>t.iveson@soton.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cunningham, MD</last_name>
      <phone>44-20-8661-3279</phone>
      <email>david.cunningham@rmh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russell Petty, MD</last_name>
      <phone>44-84-5456-6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Crosby, MD</last_name>
      <phone>44-29-2031-6292</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire Hospital</name>
      <address>
        <city>Basingstoke</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charlotte Rees</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jo Dent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mohan Hingorani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sharmila Sothi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Janet Graham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matt Seymour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tom Roques</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kinnari Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queens Hospital</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sherif Raouf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weston Park</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Suzanne Darby</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Western Hospital</name>
      <address>
        <city>Swindon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claire Blesing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emma Cattell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Okines AF, Langley RE, Thompson LC, Stenning SP, Stevenson L, Falk S, Seymour M, Coxon F, Middleton GW, Smith D, Evans L, Slater S, Waters J, Ford D, Hall M, Iveson TJ, Petty RD, Plummer C, Allum WH, Blazeby JM, Griffin M, Cunningham D. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol. 2013 Mar;24(3):702-9. doi: 10.1093/annonc/mds533. Epub 2012 Oct 28.</citation>
    <PMID>23108952</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2007</study_first_submitted>
  <study_first_submitted_qc>March 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical Research Council</investigator_affiliation>
    <investigator_full_name>Professor David Cunningham</investigator_full_name>
    <investigator_title>ST03 Chief Investigator, Professor David Cunningham</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>adenocarcinoma of the gastro oesophageal junction</keyword>
  <keyword>adenocarcinoma of the lower oesophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

